M
Mark Gurney
Researcher at National University of Ireland, Galway
Publications - 7
Citations - 136
Mark Gurney is an academic researcher from National University of Ireland, Galway. The author has contributed to research in topics: Chimeric antigen receptor & CD38. The author has an hindex of 3, co-authored 7 publications receiving 42 citations. Previous affiliations of Mark Gurney include University Hospital Galway.
Papers
More filters
Journal ArticleDOI
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Mark Gurney,Arwen Stikvoort,Emma Nolan,Lucy Kirkham-McCarthy,Stanislav Khoruzhenko,Rama Shivakumar,Sonja Zweegman,Niels W.C.J. van de Donk,Tuna Mutis,Eva Szegezdi,Subhashis Sarkar,Michael O'Dwyer +11 more
TL;DR: In this paper, a CD38 CAR-NK cell therapy for acute myeloid leukemia (AML) targeting was proposed, where the authors applied CRISPR/Cas9 genome editing to disrupt the CD38 gene during expansion achieving a mean knockdown efficiency of 84%.
Journal ArticleDOI
Generating natural killer cells for adoptive transfer: expanding horizons.
TL;DR: A review of the field of clinical-grade NK cell expansion can be found in this article, where the authors explore the desirable features of an idealized NKcell expansion approach and focus on techniques used in recently published clinical trials.
Journal ArticleDOI
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma.
Dawn Swan,Mark Gurney,Mark Gurney,Janusz Krawczyk,Janusz Krawczyk,Aideen E. Ryan,Michael O'Dwyer,Michael O'Dwyer +7 more
TL;DR: The effects cyclophosphamide has on the immune system is discussed, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies are discussed.
Journal ArticleDOI
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.
Mark Gurney,Michael O'Dwyer +1 more
TL;DR: A review of CAR modified natural killer (CAR-NK) cell therapies for acute myeloid leukemia (AML) treatment can be found in this article, where the authors examine the established role of CAR-NK cells in AML biology and the existing anti-leukemic activity of NK cell adoptive transfer.
Journal ArticleDOI
Targeting CD38(high) Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells
Emma Nolan,Arwen Stikvoort,Mark Gurney,Nutsa Burduli,Lucy Kirkham-McCarthy,John Daly,Niels W.C.J. van de Donk,Tuna Mutis,Subhashis Sarkar,Michael O'Dwyer +9 more
TL;DR: This study investigates the therapeutic efficacy of "affinity-optimized" variant(s) of CD38 CAR and membrane bound TRAIL on NK-cell based platforms which can target AML blasts with high expression ofCD38 (CD38high AML).